Copper diacetylbis(4-methyl-3-thiosemicarbazone), commonly known as Cu (ATSM), has demonstrated significant potential in rejuvenating vital waste clearance mechanisms in the brain, reducing harmful amyloid beta accumulation, and enhancing spatial memory in a laboratory model of Alzheimer’s disease. This study was conducted by a dedicated research team at Monash University.
The study leveraged the APP/PS1 mouse model for familial Alzheimer’s disease to assess how Cu(ATSM) affects cerebral microvascular integrity and P-glycoprotein activity, influencing amyloid beta clearance, brain amyloid levels, and cognitive abilities. Image credit: Pyun et al., doi: 10.1021/acschemneuro.6c00252.
Alzheimer’s disease arises from the accumulation of the toxic protein amyloid beta.
Under normal circumstances, the brain eliminates these proteins through the blood-brain barrier into the bloodstream.
In Alzheimer’s patients, a critical pump known as P-glycoprotein becomes significantly impaired, leading to a buildup of toxic proteins in the brain.
“This innovative treatment effectively targets cerebral blood vessels to decrease toxic protein levels, resulting in noteworthy behavioral improvements,” explained lead researcher Dr. Jae Pyung. The findings are detailed in their published paper in ACS Chemical Neuroscience.
“This study marks the first instance demonstrating that Cu(ATSM) can enhance P-glycoprotein clearance by 24.1% in an Alzheimer’s disease context, thereby connecting the restoration of the blood-brain barrier to decreased toxic protein levels and improved cognitive capacity.”
“By bolstering this pump mechanism, the brain can effectively eradicate trapped waste materials.”
“Over a 56-day treatment period, Cu(ATSM) reduced harmful amyloid beta levels by 42% and enhanced spatial learning abilities by nearly 44%.”
“Given that this compound has already undergone safety evaluations for other medical conditions, it shows great promise for swift progression into human clinical trials,” stated Professor Joseph Nicolazzo, the senior author.
“Cu(ATSM) is a copper-based compound with notable anti-inflammatory and neuroprotective characteristics, currently undergoing clinical trials for diseases such as Parkinson’s disease and amyotrophic lateral sclerosis.”
“These preclinical findings strongly advocate for further investigation of this drug in early symptomatic Alzheimer’s disease, as reducing amyloid levels is clinically validated to enhance functional outcomes.”
While Cu(ATSM) effectively lowers amyloid accumulation, researchers are still deciphering the precise biological pathways that facilitate protein clearance from the brain.
Apart from its role in repairing the blood-brain barrier, there is speculation that copper treatment might empower the brain’s immune cells, known as microglia, to ingest and degrade toxic plaques.
“Future investigations will concentrate on elucidating the exact clearance mechanisms that allow proteins to exit the brain and enter circulation,” the research team remarked.
“This breakthrough establishes a robust basis for exploring biometallic therapies like Cu(ATSM) to counteract vascular dysfunction and cognitive decline associated with Alzheimer’s disease.”
_____
Jaepyeong et al. Cu(ATSM) enhances blood-brain barrier P-glycoprotein levels and promotes cognitive function in the APP/PS1 mouse model of Alzheimer’s disease. ACS Chem. Neuroscience published online on May 30, 2026. doi: 10.1021/acschemneuro.6c00252
Source: www.sci.news
